Elotuzumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Final OS Results
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results From the Phase 3 Randomized ELOQUENT-2 Study
Blood Cancer J 2020 Sep 04;10(9)91, MA Dimopoulos, S Lonial, D White, P Moreau, K Weisel, J San-Miguel, O Shpilberg, S Grosicki, I Špička, A Walter-Croneck, H Magen, MV Mateos, A Belch, D Reece, M Beksac, A Spencer, H Oakervee, RZ Orlowski, M Taniwaki, C Röllig, H Einsele, M Matsumoto, KL Wu, KC Anderson, YM Jou, A Ganetsky, AK Singhal, PG RichardsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.